Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 12, 2005, Pages 1624-1629

  Masse, I ^a   Bordet, R ^b   Deplanque, D ^b   Al Khedr, A ^a   Richard, F ^a   Libersa, C ^b   Pasquier, Florence ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL OBSERVATION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 28144446883     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.063388     Document Type: Article

References (64)

1. Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-0.
2. Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann NY Acad Sci 1997;826:128-46.
3. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
4. Roher AE, Kuo YM, Kokjohn KM, et al. Amyloid and lipids in the pathology of Alzheimer disease. Amyloid 1999;6:136-45.
5. Kivipelto M, Helkala E-L, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. Neurology 2001;56:1683-9.
6. van Exel E, de Craen AJM, Gussekloo J, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002;51:716-21.
7. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol. Chem 1996;271:4436-40.
8. Frears ER, Stephens DJ, Walters CE, et al. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999;10:1699-705.
9. Howland DS, Trusko SP, Savage MJ, et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 1998;273:16576-82.
10. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-31.
11. Sparks DL, Martin TA, Gross DR, et al. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech 2000;50:287-90.
12. Launer LJ, White LR, Petrovitch H, et al. Cholesterol and neuropathologic markers of AD. A population-based autopsy study. Neurology 2001;57:1447-52.
13. Evans RM, Hui S, Perkins A, et al. Cholesterol and APOE genotype interact to influence Alzheimer disease. Neurology 2004;62:1869-71.
14. Streit WJ, Sparks DL. Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med 1997;75:130-138.
15. Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer's disease: is there a link? Neurology 2001;57:1089-93.
16. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003;6:345-51.
17. Decarli C. Vascular factors in dementia: an overview. J Neurol Sci 2004;226:19-23.
18. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000;21:321-30.
19. Sadowski M, Pankiewicz J, Scholtzova H, et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res 2004;29:1257-66.
20. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-4.
21. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-61.
22. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002;16:131-6.
23. Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002;59:1257-8.
24. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31.
25. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
26. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
27. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63:1624-8.
28. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
30. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
31. Brun A, Englund E, Gustafson L, et al. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-18.
32. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
33. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
34. Pasquier F, Richard F, Lebert F. Natural history of frontotemporal dementia: comparison with Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17:253-7.
35. Mattis S. Mental status examination for organic mental syndrome in the elderly patients. In: Bellak L, Karasu TB, eds. Geriatric psychiatry: a handbook for psychiatrists and primary care physicians. New York: Grune & Stratton, 1976:77-101.
36. Bendel RB, Afifi AA. Comparison of stopping rules in forward regression. J Am Stat Assoc 1977;72:46-53.
37. Haley RW, Dietschy JM. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 2000;57:1410-12.
38. Cheung BM, Kumana CR. Dementia and statins. Lancet 2001;357:880.
39. Birkennager WH, Wang JG, Staessen JA. Dementia and statins. Lancet 2001;357:880.
40. Lesser GT, Libow LS. Statin-Alzheimer disease association not yet proven. Arch Neurol 2001;58:1022-3.
41. Ebrahim S, Shlomo YB, Smith GD, et al. Dementia and statins. Lancet 2001;357:882.
42. Golomb BA, Jaworski B. Statins and dementia. Arch Neurol 2001;58:1169-70.
43. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J Am Med Assoc 1997;277:813-17.
44. Esiri MM, Nagy Z, Smith MZ, et al. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999;354:919-20.
45. Lee JH, Olichney JM, Hansen LA, et al. Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol 2000;57:1474-9.
46. Jellinger KA. Small concomitant Cerebrovascular lesions are not important for cognitive decline in severe Alzheimer disease. Arch Neurol 2001;58:520-1.
47. Mungas D, Reed BR, Ellis WG, et al. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol 2001;58:1243-7.
48. Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457-65.
49. Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual minimental state examination score in patients with probable Alzheimer disease. Arch Neurol 1999;56:857-62.
50. Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000;12:231-47.
51. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-7.
52. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-14.
53. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
54. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378-84.
55. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
56. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-50.
57. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. Am J Psychiatry 1997;154(5 suppl):1-39.
58. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-6.
59. Borroni B, Pettenati C, Bordonali T, et al. Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease. Neurosci Lett 2003;343:213-15.
60. Pahan K, Sheikh FG, Namboodiri AM, et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-9.
61. Rikitake Y, Kawashima S, Takesnita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96.
62. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-57.
63. Deplanque D, Gele P, Petrault O, et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003;23:6264-71.
64. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.